Evidence map›Paper›PMID 24438754›Full record

Trial reportBMC pregnancy and childbirth2014

Adapting iron dose supplementation in pregnancy for greater effectiveness on mother and child health: protocol of the ECLIPSES randomized clinical trial.

Victoria Arija, Francesc Fargas, Gemma March, Susana Abajo, Josep Basora, Josefa Canals, Blanca Ribot, Estefania Aparicio, Nuria Serrat, Carmen Hernández-Martínez and 1 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC pregnancy and childbirth, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Daily oral iron supplementation during pregnancy.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Daily oral iron supplementation during pregnancy.The Cochrane database of systematic reviews · 2015
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Victoria ArijaUnitat de Suport a la Recerca Tarragona-Reus, Institut d'Investigació en Atenció Primària Jordi Gol, Tarragona, Spain. victoria.arija@urv.cat.
Francesc Fargas
Gemma March
Susana Abajo
Josep Basora
Josefa Canals
Blanca Ribot
Estefania Aparicio
Nuria Serrat
Carmen Hernández-Martínez
Núria Aranda
Government of Catalonia · ESUniversidad Rovira i Virgili · ESInstitut d'Investigació Sanitària Pere Virgili · ESInstitut Català de la Salut · ESInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, there is no consensus regarding iron supplementation dose that is most beneficial for maternal and offspring health during gestation. Recommended iron supplementation dose does not preempt anemia in around 20% of the pregnancies, nor the risk of hemoconcentration in 15%. This deficit, or excess, of iron prejudices the mother-child wellbeing. Therefore the aims of the study are to determine the highest level of effectiveness of iron supplementation adapted to hemoglobin (Hb) levels in early pregnancy, which would be optimum for mother-child health. METHODS/

design

designRandomized Clinical Trial (RCT) triple-blindedSetting: 10 Primary Care Centers from Catalunya (Spain)Study subjects: 878 non-anemic pregnant women at early gestation stage, and their subsequent newborns

methodsThe study is structured as a RCT with 2 strata, depending on the Hb levels before week 12 of gestation. Stratum #1: If Hb from 110 to 130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 80 mg/d. Stratum #2: If Hb >130 g/L, randomly assigned at week 12 to receive iron supplement of 40 or 20 mg/d. MEASUREMENTS: In the mother: socio-economic data, clinical history, food item frequency, lifestyle and emotional state, and adherence to iron supplement prescription. Biochemical measurements include: Hb, serum ferritin, C reactive protein, cortisol, and alterations in the HFE gene (C282Y, H63D). In children: ultrasound fetal biometry, anthropometric measurements, and temperament development.Statistical analyses, using the SPSS program for Windows, will include bivariate and multivariate analyses adjusted for variables associated with the relationship under study. DISCUSSION: Should conclusive outcomes be reached, the study would indicate the optimal iron supplementation dose required to promote maternal and infant health. These results would contribute towards developing guidelines for good clinical practice.

Indexed as

Birth WeightDietary SupplementsAdultAnemia, Iron-DeficiencyAnthropometryC-Reactive ProteinDietDose-Response Relationship, DrugFemaleFerritinsFetal DevelopmentHemochromatosis ProteinHemoglobinsHistocompatibility Antigens Class IHumansHydrocortisoneC-Reactive ProteinFerritinsHemochromatosis ProteinHemoglobinsHFE protein, humanHistocompatibility Antigens Class IHydrocortisoneIronMembrane Proteins

Identifiers

PMID24438754
PMCPMC3898489
OpenAlexW1990762901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.